Brief: Pmv Pharmaceuticals Initial Pc14586 Phase 1 Data Presented At Asco Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With A P53 Y220c Mutation
07/06/2022 17:01
June 7 (Reuters) - PMV Pharmaceuticals Inc PMVP.O :
* PMV PHARMACEUTICALS INITIAL PC14586 PHASE 1 DATA PRESENTED
AT
ASCO DEMONSTRATED ANTI-TUMOR ACTIVITY ACROSS MULTIPLE SOLID
TUMOR TYPES WITH A P53 Y220C MUTATION
* PMV PHARMACEUTICALS INC - OVERALL RESPONSE RATE (ORR) OF
32%
(8/25) ACHIEVED IN HIGHER DOSE COHORTS PER RECIST V1.1
* PMV PHARMACEUTICALS INC - FAVORABLE SAFETY AND
TOLERABILITY OF
PC14586, AND CLINICAL ACTIVITY ACROSS SIX DISTINCT TUMOR TYPES
Source text for Eikon: ID:nGNX4rQt3R
Further company coverage: PMVP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pmv Pharmaceuticals
See all newsAustralia's Premier Investments jumps as Citi backs in-line earnings
U.S. STOCKS ON THE MOVE- Medtronic, Comstock, Apple
U.S. STOCKS ON THE MOVE-GoPro, TXNM Energy, Emergent BioSolutions
U.S. STOCKS ON THE MOVE-Fervo Energy, Myriad Genetics, Emergent BioSolutions
U.S. STOCKS ON THE MOVE-Robinhood Markets, Park Hotels & Resorts, Capricor Therapeutics